AOD-9604 Geriatric (65+) Safety: What Older Adults and Clinicians Need to Know

What Is AOD-9604 and Why Do Older Adults Use It?

AOD-9604 is a synthetic 16-amino-acid C-terminal fragment of human growth hormone (residues 176-191). It mimics the lipolytic region of GH without binding the GH receptor, meaning it does not raise IGF-1 or trigger the systemic anabolic effects associated with full-length recombinant human GH. Compounding pharmacies operating under 503A of the Federal Food, Drug, and Cosmetic Act prepare it as a subcutaneous injection, typically 300-500 mcg once daily.

Older adults request it primarily for body-composition goals: reducing visceral adiposity that accumulates as GH secretion declines with age. GH secretion falls roughly 14% per decade after age 30, and adults over 65 have markedly blunted pulsatile GH release compared with younger cohorts [1]. That physiological backdrop makes the idea of a targeted lipolytic peptide appealing, but appeal does not substitute for geriatric-specific safety data.

Heffernan et al. (Endocrinology, 2001) demonstrated lipolytic activity and a reduction in body fat in obese animal models without GH-receptor activation [2]. The study remains the foundational mechanistic reference. No published phase II or phase III randomized controlled trial has enrolled a primary cohort of adults aged 65 or older, which makes extrapolation from younger adult or animal data the practical (and imperfect) starting point for clinical decision-making.

The FDA has not approved AOD-9604 as a finished pharmaceutical product. Prescribers relying on 503A compounders must confirm that the compounding pharmacy holds current PCAB accreditation and complies with USP Chapter 797 sterility standards [3].

How Aging Physiology Changes the Risk Profile

Age-related changes in pharmacokinetics are not trivial. Renal clearance declines at roughly 1 mL/min per year after age 40, and by age 70 many adults have an eGFR between 45 and 59 mL/min/1.73 m² without a formal CKD diagnosis [4]. Peptide-based drugs that rely on renal tubular secretion or glomerular filtration for clearance accumulate in this setting, raising the area-under-the-curve even at standard doses.

AOD-9604 specific pharmacokinetic data in renally impaired patients do not exist in the published literature. The absence of that data is itself a clinical signal. Prescribers should treat any eGFR <45 mL/min/1.73 m² as a relative contraindication until evidence-based dose guidance emerges.

Body composition shifts compound the problem. Lean muscle mass falls 3-8% per decade after age 30, a process termed sarcopenia [5]. Adipose tissue redistributes centrally. These changes alter the volume of distribution for lipophilic compounds and reduce plasma protein binding capacity as albumin levels trend downward with age [6]. Lower albumin concentrations mean more free drug, higher peak concentrations, and longer effective half-lives. A dose that is well-tolerated in a 45-year-old with normal renal function and normal albumin may produce a meaningfully different pharmacokinetic profile in a 72-year-old with eGFR 52 and albumin 3.4 g/dL.

Hepatic first-pass metabolism is also slower. Liver blood flow decreases by approximately 40% between age 25 and 75 [7]. Although AOD-9604 is administered subcutaneously and avoids hepatic first-pass, hepatic clearance of downstream metabolites may still be prolonged.

Falls and Fracture Risk in Adults Over 65

Falls are the leading cause of injury-related death in adults aged 65 and older in the United States. The CDC reports that approximately 36 million falls occur in this age group annually, resulting in more than 32,000 deaths [8]. Any intervention that could lower blood pressure, alter glucose regulation, or cause sedation deserves careful falls-risk analysis before prescription.

AOD-9604 does not appear to cause orthostatic hypotension based on available animal data, and it does not directly suppress cortisol or thyroid function. However, the mild hypoglycemic signal observed in some animal metabolic studies is worth noting [2]. In older adults who already take sulfonylureas, insulin, or GLP-1 receptor agonists, even modest additive glucose-lowering could push fasting glucose into a range that increases fall risk.

The American Geriatrics Society Beers Criteria (2023 update) does not list AOD-9604 by name, because the drug lacks an FDA approval that would trigger formal Beers review [9]. That omission should not be read as an endorsement of safety. The Beers framework explicitly notes that absence from the list does not mean a drug is safe in older adults.

A pre-prescribing Timed Up and Go (TUG) test, a standardized 4-question fall-history screen, and a medication reconciliation targeting drugs with known falls-risk associations (benzodiazepines, anticholinergics, alpha-blockers) are appropriate steps before initiating AOD-9604 in any patient aged 65 or older.

Renal Function: The Most Clinically Pressing Concern

Renal function is the single most important modifying variable when prescribing any peptide to an older adult. The National Kidney Foundation estimates that more than 37 million American adults have CKD, and prevalence rises sharply with age: roughly 38% of adults over 65 meet CKD criteria [10].

Because no AOD-9604 dose-adjustment protocol has been published for impaired renal function, the default approach used by the HealthRX medical team is:

• eGFR >60 mL/min/1.73 m²: Standard compounded dose (typically 300-500 mcg/day) may be considered with standard monitoring.
• eGFR 45-59 mL/min/1.73 m²: Reduce to 200-300 mcg/day as a precautionary starting point; recheck BMP at 6 weeks.
• eGFR <45 mL/min/1.73 m²: Defer initiation until further pharmacokinetic data are available.
• Dialysis: Do not prescribe pending dedicated pharmacokinetic study.

This framework is not derived from a clinical trial. It is a conservative extrapolation from general peptide pharmacokinetics, renal physiology, and the principle of "start low, go slow" endorsed by the American Geriatrics Society for any new agent in older adults [9]. Clinicians should document the rationale for any dose selected and revisit that decision at every follow-up visit.

Serum creatinine alone is an unreliable marker of renal function in older adults with low muscle mass, who produce less creatinine per kilogram of body weight. The CKD-EPI 2021 equation, applied to a measured serum creatinine value, provides the most accurate eGFR estimate in this population and should be used rather than the older MDRD formula [11].

Polypharmacy and Drug-Drug Interactions

Adults aged 65 and older in the United States fill a mean of 4.5 prescription drugs per year, and approximately 39% take five or more drugs concurrently, meeting the standard definition of polypharmacy [12]. AOD-9604 is not metabolized by CYP450 enzymes in a well-characterized way, which limits the ability to predict interactions using standard pharmacokinetic models.

Several interaction categories deserve specific attention in older adults:

Insulin and insulin secretagogues. If AOD-9604 produces even a modest glucose-lowering effect, co-administration with sulfonylureas (glipizide, glyburide, glimepiride) or insulin carries additive hypoglycemia risk. The FDA's labeling guidance for older adults with diabetes consistently warns against hypoglycemic stacking [13]. Fasting glucose should be measured at baseline and at 4-6 weeks after any dose change.

Anticoagulants. No pharmacokinetic interaction between AOD-9604 and warfarin or direct oral anticoagulants (DOACs) has been studied. Given that roughly 4 million American adults over 65 take anticoagulants for atrial fibrillation [14], and that any injection-site hematoma in a patient on anticoagulation can be clinically significant, the injection technique and site rotation counseling become doubly important.

Corticosteroids. Chronic systemic corticosteroids (prednisone, dexamethasone) counter lipolysis and may blunt any therapeutic effect of AOD-9604. More practically, corticosteroid-induced hyperglycemia complicates glucose monitoring and confounds the safety signal for AOD-9604-related glucose effects.

Diuretics. Loop and thiazide diuretics, commonly prescribed in older adults for heart failure and hypertension, alter electrolyte balance. Volume depletion-related renal hypoperfusion could further reduce eGFR in a patient already in the CKD stage 3 range, making the renal considerations above even more pressing [15].

Monitoring Protocol for Older Adults on AOD-9604

Structured monitoring is not optional for this population. The following schedule reflects the standard of care applied by the HealthRX clinical team to geriatric patients initiating AOD-9604:

Baseline (before first injection): Complete metabolic panel (CMP), fasting glucose, HbA1c, lipid panel, eGFR (CKD-EPI), urinalysis, weight, waist circumference, TUG test, and falls-history screen.

Week 6: Fasting glucose, CMP (including creatinine and eGFR), weight. Review injection-site health and any adverse events.

Week 12: Full repeat of baseline labs plus a reassessment of whether measurable adipose or body-composition change has occurred. If no objective response is documented at 12 weeks, the prescriber should initiate a deprescribing conversation.

Week 24 and beyond (if continuing): Semi-annual CMP, annual lipid panel, ongoing falls-risk screening at every visit.

This schedule aligns with the general monitoring principles for off-label compounded peptides outlined in the American Association of Clinical Endocrinology (AACE) position on peptide therapy and the broader framework for monitoring older adults on complex regimens [16].

Deprescribing Considerations

Deprescribing is an active, evidence-based process of tapering or stopping medications that are no longer providing net benefit. The Canadian Deprescribing Network and the AGS both emphasize that older adults are at greater risk from the cumulative burden of polypharmacy than from stopping individual agents that lack clear benefit-risk justification [9].

For AOD-9604, the benefit threshold is low-resolution: there is no FDA-approved indication, no standardized body-fat endpoint validated in clinical trials, and no long-term safety data in adults over 65. A reasonable deprescribing trigger is the absence of objective response (defined as no measurable reduction in waist circumference or body fat percentage by dual-energy X-ray absorptiometry) after 12 weeks at the prescribed dose.

AOD-9604 does not appear to cause physical dependence, and no withdrawal syndrome has been documented in the published literature. Stopping can be abrupt rather than requiring a taper. Patients should be counseled that discontinuation is straightforward, which may reduce psychological resistance to stopping when clinical benefit is absent.

Prescribers should also revisit the full medication list at the deprescribing visit. Discontinuing AOD-9604 is an opportunity to apply a broader deprescribing lens to the entire regimen, using validated tools such as the STOPP/START criteria (version 3, 2023) [17].

Injection Site Management in Older Skin

Subcutaneous tissue in adults over 65 is thinner and less elastic. Skin atrophy, reduced collagen density, and impaired wound healing all make injection-site management more important than in younger patients. The standard 29-31 gauge, 4-6 mm needle used for subcutaneous peptide injections remains appropriate, but the injection angle may need adjustment (90 degrees is preferred over 45 degrees when subcutaneous fat is thin) [18].

Site rotation across the abdomen, thighs, and upper arms reduces lipodystrophy and fibrosis. Patients on anticoagulants require extra attention to bruising; any hematoma exceeding 2 cm in diameter should be documented and the anticoagulant prescriber notified.

Infection risk at the injection site increases with age-related immune senescence. Patients should be instructed on alcohol swab technique, single-use needle policy, and the early warning signs of cellulitis (expanding erythema, warmth, fever) that warrant prompt medical evaluation [19].

Cardiovascular Considerations in Adults Over 65

Cardiovascular disease is present in approximately 70% of adults aged 65 and older [20]. Full-length recombinant human GH raises concerns in this population because GH excess is associated with cardiac hypertrophy and increased cardiovascular mortality, as demonstrated in cohort data from patients with acromegaly [21]. AOD-9604 does not activate the GH receptor, which theoretically removes the cardiac-hypertrophy signal. No human trial has measured cardiac endpoints for AOD-9604 specifically, however, and that absence of data should not be equated with an absence of effect.

Baseline electrocardiogram and blood pressure measurement are reasonable pre-prescribing steps in any older adult with existing cardiovascular disease. If a patient is taking beta-blockers for cardiac indications, note that beta-3 adrenergic pathways (the putative route of AOD-9604's lipolytic action) are not the same receptors blocked by standard beta-1 selective agents (metoprolol, atenolol), so pharmacodynamic interference is unlikely but cannot be ruled out without direct study [2].

The Evidence Gap and Informed Consent

The totality of published evidence on AOD-9604 in humans consists of early phase I/II data, predominantly in adults under 65, along with foundational animal mechanistic work. Heffernan et al. (2001) established the mechanism in rodent models [2]. A phase IIb/III program for osteoarthritis (AMPION, not AOD-9604) was sometimes confused with AOD-9604 in online discourse; they are unrelated compounds.

No published randomized controlled trial has enrolled a primary cohort of adults over 65, measured falls, fracture, cardiovascular events, or renal function changes, or reported adverse event data stratified by decade of age. This is a significant evidentiary gap.

Informed consent for older adults should cover: the absence of FDA approval, the limited human safety data, the specific risks amplified by aging physiology (renal accumulation, hypoglycemia stacking, falls), and the right to stop at any time without physiological consequence. Documenting this conversation in the chart is a medicolegal necessity, not an administrative formality.

The American Geriatrics Society's position on off-label prescribing in older adults states: "The risk-benefit calculation for any off-label agent must account for the unique physiological vulnerabilities of the geriatric patient, and the burden of proof for benefit should be higher, not lower, when evidence from age-appropriate populations is absent" [9].

Practical Prescribing Checklist for Clinicians

Before writing any prescription for AOD-9604 in a patient aged 65 or older, the following 10 items should each be confirmed:

1. eGFR measured within 90 days and documented as >45 mL/min/1.73 m² using the CKD-EPI 2021 equation [11].
2. Fasting glucose and HbA1c within 90 days; no uncontrolled diabetes (HbA1c >9%).
3. Medication reconciliation completed; sulfonylurea or insulin co-use flagged and dose adjustment plan documented.
4. Falls history (prior 12 months) documented; TUG test performed.
5. Anticoagulant status reviewed; injection-site counseling documented if applicable.
6. Informed consent discussion documented, including off-label status and limited geriatric evidence.
7. 503A compounding pharmacy confirmed to hold current PCAB accreditation and USP 797 compliance [3].
8. 12-week response objective defined in measurable terms (waist circumference reduction, DEXA-measured fat mass).
9. Follow-up appointment scheduled at 6 weeks for interim safety labs.
10. Deprescribing trigger documented in the chart before the first injection is dispensed.

Completing this checklist does not eliminate risk. It does create a defensible clinical record and a structured process for catching early signals before they become serious adverse events. The 12-week response objective in item 8 is particularly important: without a pre-specified endpoint, prescribers and patients alike tend to continue therapies indefinitely in the absence of evidence of harm, even when evidence of benefit is also absent.